NEW YORK(GenomeWeb) – Proteomics firm Caprion said this week that it has signed an agreement to in-license Integrated Diagnostics' Xpresys Lung cancer test.
The agreement gives Caprion exclusive rights to market and commercialize Xpresys Lung in Canada.
Xpresys is intended to aid doctors in identifying lung nodules detected via CT scans as likely benign. The test uses multiple-reaction monitoring mass spec to quantify the levels of 11 proteins in patient blood samples. Indi launched the test in the US in 2013.